Categories: Technology

NSA Labs Helps Leading Biopharmaceutical Companies Get Study Results Faster on Proscias Platform

Specialized CRO has delivered 750 neuroscience studies advancing drug R&D with digital pathology

 | Source: Proscia

KNOXVILLE, Tenn. and PHILADELPHIA , Feb. 17, 2026 (GLOBE NEWSWIRE) — NeuroScience Associates (NSA Labs), a specialized contract research organization (CRO) focused on high-throughput neurohistology, has a proven track record of accelerating time to study results for leading biopharmaceutical companies. Since adopting Proscia’s Concentriq® software platform in 2018, NSA Labs has continued to improve efficiency across its digital imaging, analysis, and antibody trial workflows while streamlining collaboration with sponsors.

NSA Labs conducts high-quality neurohistology studies on accelerated timelines. Its proprietary MultiBrain® and MultiCord® tissue processing technologies support this pace by enabling multiple brain and spinal cord samples to be processed together.

With Concentriq, the CRO has additionally driven efficiency across 750 studies by centralizing images, data, and workflows for its scientists and rapidly sharing results with sponsors on the platform. As 16 of the top 20 pharmaceutical companies rely on Concentriq for pathology from discovery to diagnostics, sponsors can seamlessly carry these study results into downstream R&D activities.

“In complex drug development, speed depends on shared visibility and a clear path from results to decisions,” said Tate York, Director of Imaging and Analysis at NeuroScience Associates. “Concentriq brings our scientists and sponsor teams into one workspace, so sponsors can quickly interpret findings, make decisions, and advance their programs with clarity and confidence.”

NSA Labs also leverages Concentriq as part of its slide scanning service, providing sponsors with direct access to histology images on the platform. Sponsor teams can view, analyze, and share these images alongside study results.

“NSA Labs continues to raise the bar for speed, quality, and collaboration in neurohistology,” said David West, CEO of Proscia. “This standard of excellence is why many of the world’s largest pharmaceutical companies rely on its team for complex drug development programs.”

About NeuroScience Associates
NeuroScience Associates (NSA Labs) is a global leader in mass-production neurohistology services. Through its proprietary MultiBrain® and MultiCord® technologies, NSA Labs can provide organizations with faster throughput times on research tissue in a very cost-effective manner. For more information, visit nsalabs.com.

About Proscia
Proscia is rewiring pathology for precision medicine by elevating the experts behind the insights. Its technology spans drug discovery to diagnostics, building confidence, scaling high-value work, and accelerating decisions to move breakthroughs forward and improve patient care. Proscia’s solutions are trusted by 16 of the top 20 pharmaceutical companies, and it was named Global 2026 Best in KLAS for Digital Pathology in Europe. Learn more at proscia.com, and follow Proscia on LinkedIn and X.

Contact:
Sydney Fenkell
VP, Marketing Communications
sydney@proscia.com
215.816.3436

GlobeNews Wire

Recent Posts

ITM Announces Phase 3 COMPETE Patient-Reported Quality of Life Data with n.c.a. Lu-edotreotide (ITM-11) vs. Everolimus at ASCO 2026

Exploratory analysis showed favorable patient-reported quality of life outcomes and delayed time to deterioration in…

1 hour ago

Fobi AI Provides Corporate Update Regarding FFCTO Revocation Process and Q3 Interim Filings

May 29, 2026 21:18 ET  | Source: Fobi AI Inc. VANCOUVER, BC, May 29, 2026…

8 hours ago

Crypto News Today: AlphaPepe Presale Stage 17 Nears Sell Out While XRP Price Prediction Eyes $7.00

MONACO, May 29, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning toward AlphaPepe as…

8 hours ago